South Africa Centers of Excellence in Drug-Resistant TB

South Africa Centers of Excellence in Drug-Resistant TB Provincial Centre of Excellence will be responsible for initiating and monitoring treatment of drug-resistant TB (DR-TB). Core Faculty - Jason E.

Farley, PhD, MPH, NP, FAAN Associate Professor | Johns Hopkins University School of Nursing, Adjunct Associate Professor | University of KwaZulu Natal (UKZN), South Africa. Adult Nurse Practitioner | JHU School of Medicine

We will be responsible for initiating and monitoring treatment of drug-resistant TB (DR-TB) and paediatric patients, MDRTB patients with complications, co morbidities, or those who live near the unit. The centralised unit will support and advise the provincial TB Directorate regarding the clinical management of DR-TB in the province. Provincial Level:

The centralised DR-TB unit is also known as the “Provincial Centre of Excellence”. Each province has at least one hospital that is a specialised unit for DR-TB. This hospital will take a supporting and supervisory role for the MDR-TB outpatient programme in each province, and as the centre of excellence, provide technical advice to the decentralised MDR-TB sites. Functions of the Centralised DR-TB Unit:

• Initiating treatment of all DR-TB cases after appropriate assessment;
• Admitting DR-TB cases from the geographic area around the unit;
• Ensuring hospitalisation of all XDR-TB cases until there are two successive negative
TB cultures;
• Assessing all DR-TB patients attending the clinic each month;
• Providing DOT to all DR-TB patients attending the unit each day;
• Recording and reporting to the provincial Department of Health;
• Providing ongoing training, support and supervision for all the facilities in the
province;
• Providing social support, rehabilitation, educational and skills building programmes for
patients;
• Providing education and counseling to all patients admitted in hospital;
• Preparing a discharge plan for all patients and ensuring effective down referrals;
• Monitoring DR-TB patients post discharge until completion of treatment and two years
post treatment completion;
• Monitoring rational usage of second-line drugs and ancillary drugs for side effects
management;
• Establishing and maintaining functional clinical management teams;
• Compiling monthly, quarterly, six-monthly and annual reports of DR-TB patients started
on treatment, their culture conversion and outcomes;
• Providing technical assistance and capacity building to decentralised DR-TB units,
and feeder clinics on management of DR-TB; and
• Arranging patients’ evaluations at provincial patient review committees.

TB study reveals potential targets to treat and control infectionThis is the first study to use in depth, single-cell RN...
02/25/2021

TB study reveals potential targets to treat and control infection

This is the first study to use in depth, single-cell RNA sequencing (scRNAseq) to analyze responses to TB in macaques

Read more here -

Researchers may have found a new pathway to treat and control tuberculosis (TB), the disease caused by Mycobacterium tuberculosis (Mtb). Using single-cell RNA sequencing (scRNAseq), a next-generation sequencing technology, scientists were able to further define the mechanisms that lead to TB infecti...

Today is World TB Day 2019!
03/24/2019

Today is World TB Day 2019!

https://www.who.int/tb/publications/global_report/en/WHO 2018 Global TB Reports has the following facts on  Global MDR/R...
12/21/2018

https://www.who.int/tb/publications/global_report/en/

WHO 2018 Global TB Reports has the following facts on Global MDR/RR TB:

* Only 1 in 4 people had access to MDR-TB treatment
* 558,000 estimated new MDR/TB cases in 2017
* 161,000 MDR/RR-TB cases detected in 2017
* 139,000 patients started on MDR-TB treatment in 2017
* 55% treatment success in MDR/RR-TB patients starting treatment in 2015

It provides a comprehensive and up-to-date assessment of the tuberculosis epidemic and progress

12/21/2018

WHO updated its treatmnet guidelines for multidrug and RR TB

Excellent to see Nontobeko’s poster at  .  She reviews the features of the EDR TB database and epidemiology of DR-TB in ...
10/23/2018

Excellent to see Nontobeko’s poster at . She reviews the features of the EDR TB database and epidemiology of DR-TB in South Africa.

08/16/2018

Dr. Ndjeka presented today on "Implementing an injectable-free regimen for DR-TB" in South Africa. Stay tuned to hear more about the roll-out in South Africa.

The Treatment Action Group (TAG) is sponsoring a free webinar - "Implementing a Bedaquiline-Based, Injectable-Free Regim...
07/18/2018

The Treatment Action Group (TAG) is sponsoring a free webinar - "Implementing a Bedaquiline-Based, Injectable-Free Regimen for Drug-Resistant TB"

Sign up to hear Dr. Ndjeka talk about South Africa as the first country to roll out this regimen.

August 1st 2018 - 4pm South Africa / 3pm Kenya / 10am EST US

Register using this link:

We invite you to join a critical discussion on implementing a bedaquiline-based, injectable-free regimen for drug-resistant tuberculosis. Dr. Norbert Ndjeka from the National Department of Health in South Africa will be talking about their experience on being the first country to roll out this uniqu...

The 2nd PHC Class at UKZN for 2018 is now prepared
07/13/2018

The 2nd PHC Class at UKZN for 2018 is now prepared

07/08/2018

If infected with TB, the chances of developing TB disease are 100 times higher for people living with HIV. Understand your risk, get tested, and get treated: https://go.usa.gov/xU47U

Johns Hopkins University School of Nursing's REACH Initiative trains Primary Healthcare Nurses in Short Course Drug resi...
07/06/2018

Johns Hopkins University School of Nursing's REACH Initiative trains Primary Healthcare Nurses in Short Course Drug resistant TB Management at the University of KwaZulu-Natal

South Africa is once again on the pulse of fighting TB and improving the lives of patients being treated for MDR-TB.On t...
06/29/2018

South Africa is once again on the pulse of fighting TB and improving the lives of patients being treated for MDR-TB.
On the 18th of June 2018, The National Department of Health announced there will be a new regimen which will be "injection-free" for treatment of MDR-TB. Stay tuned to here who will be the selected clinical sites to introduce the new regimen.

The Stop TB Partnership aims to push tuberculosis up the world political agenda. It focuses on expanding the use of the Stop TB Strategy, forming a drug facility to provide free or low cost tuberculosis drugs, and a global charter to map the world response to this epidemic.

Address

525 N Wolfe Street
Baltimore, MD
21205

Website

Alerts

Be the first to know and let us send you an email when South Africa Centers of Excellence in Drug-Resistant TB posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram